[Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation]

Orv Hetil. 2003 Nov 30;144(48):2367-70.
[Article in Hungarian]

Abstract

Interferon with ribavirin therapy has been proposed for the treatment of hepatitis C recurring in liver transplants.

Aim of the study: Was to assess the efficacy of standard combination therapy (interferon plus ribavirin) of chronic hepatitis C in transplanted patients with recurrent severe HCV induced chronic hepatitis.

Methods: 12 patients with HCV-PCR positive reaction (genotype 1b) were treated with the therapy of interferon-alpha-2b (3 MU three times a week) and 800-1000 mg ribavirin daily. Liver biopsy had been done in every patients before and after the treatment. Study endpoints were the end of treatment and the 6 month post-therapy sustained virologic response.

Results: At the end of treatment 3 patients were negative for HCV-PCR and all of them had negative reaction after 6 month follow-up period.

Conclusion: The results are in a good accordance with treatment of patients with chronic hepatitis C without liver transplantation.

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Antiviral Agents / therapeutic use*
  • Aspartate Aminotransferases / blood
  • Bilirubin / blood
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / pathology
  • Hepatitis C, Chronic / surgery*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Recurrence
  • Retrospective Studies
  • Ribavirin / therapeutic use*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Ribavirin
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Bilirubin